BioCentury
ARTICLE | Clinical News

Allergan completes enrollment in Phase III trials for AMD

May 12, 2017 8:36 PM UTC

Allergan plc (NYSE:AGN) completed enrollment of 1,800 total patients with wet age-related macular degeneration (AMD) in the Phase III CEDAR and SEQUOIA trials comparing abicipar pegol (AGN-150998, MP0112) vs. Lucentis ranibizumab. The double-blind, sham-controlled, international trials enrolled 900 patients each and are comparing 2 mg intravitreal abicipar pegol given every 8 or 12 weeks vs. monthly Lucentis for 96 weeks.

The company expects to report top-line data from the trials in 2018...